Dynamic Contrast-enhanced MRI Processing Comparison for Distinguishing True Progression From Pseudoprogression in High-grade Glioma

动态增强磁共振成像处理方法在区分高级别胶质瘤真性进展与假性进展中的比较

阅读:1

Abstract

BACKGROUND: Treatment-related changes may occur due to radiation and temozolomide in glioblastoma and can mimic tumor progression on conventional MRI. DCE-MRI enables quantification of the extent of blood-brain barrier (BBB) disruption, providing information about areas of suspicious postcontrast T1 enhancement. We compared DCE-MRI processing methods for distinguishing true disease progression from pseudoprogression in high-grade gliomas (HGGs). METHODS: We identified 110 patients with HGG treated with surgery and chemoradiation who underwent DCE-MRI to further interrogate areas of new/increasing enhancement. All patients had confirmatory surgery/biopsy with pathology-confirmed progression or pseudoprogression. Scans were performed at 3T and analyzed using nordicICE. The MCA, SSS, and Parker models are three standardized processing methodologies used to create k trans maps, a parameter that quantifies BBB permeability. Three equal regions of interest were placed at sites of peak contrast enhancement within each lesion. Data from each method was processed for mean and maximum k trans . We conducted several rounds of analysis and finalized a strategy on penalized support vector machines based on engineered features with bootstrap sampling. RESULTS: The Parker method was significant for k trans maximum in the combined pathology and clinical as well as the pathology-only data sets. MCA and SSS did not perform well under the SVM classifier for pathology only. For clinical follow-up subjects, the Parker method yielded statistically significant results for maximum and mean k trans . CONCLUSIONS: The Parker method was effective in distinguishing PD and PsP for pathology and clinical data sets. MCA and SSS techniques were effective for the clinical data set.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。